Product Code: GDHCER066-14
Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in developed countries. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified into dry AMD (geographic atrophy) and wet AMD (neovascular).
GlobalData epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.
GlobalData's epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD; GlobalData epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.
- The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50-59 years, 60-69 years, 70-79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.
- The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Upcoming Reports
- 3.1. Disease Background
- 3.2. Risk Factors and Comorbidities
- 3.3. Global Trends
- 3.3.1. US
- 3.3.2. 5EU
- 3.3.3. Japan
- 3.4. Forecast Methodology
- 3.4.1. Sources Used
- 3.4.2. Forecast Assumptions and Methods
- 3.5. Epidemiological Forecast for AMD (2013-2023)
- 3.5.1. Total Prevalent Cases of AMD
- 3.5.2. Age-Specific Total Prevalent Cases of AMD
- 3.5.3. Sex-Specific Total Prevalent Cases of AMD
- 3.5.4. Age-Standardized Total Prevalence of AMD
- 3.5.5. Total Prevalent Cases of AMD by Stage
- 3.5.6. Total Prevalent Cases of Late AMD by Subtype
- 3.6. Discussion
- 3.6.1. Epidemiological Forecast Insight
- 3.6.2. Limitations of the Analysis
- 3.6.3. Strengths of the Analysis
- 4.1. Bibliography
- 4.2. About the Authors
- 4.2.1. Epidemiologists
- 4.2.2. Reviewers
- 4.2.3. Acting Director of Epidemiology
- 4.2.4. Global Head of Healthcare
- 4.3. About GlobalData
- 4.4. About EpiCast
- 4.5. Disclaimer
List of Tables
- Table 1: Risk Factors and Comorbidities for AMD
- Table 2: Diagnostic Criteria for AMD
- Table 3: 7MM, Sources of AMD Prevalence Data
- Table 4: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
- Table 5: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013
- Table 6: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N (Row %), 2013
- Table 7: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N (Row %), 2013
- Table 8: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N (Row %), 2013
List of Figures
- Figure 1: 7MM, Total Prevalent Cases of AMD, Ages ≥50 Years, Both Sexes, N, 2013-2023
- Figure 2: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013
- Figure 3: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2013
- Figure 4: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ≥50 Years, by Sex, 2013
- Figure 5: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ≥50 Years, N, 2013
- Figure 6: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ≥50 Years, N, 2013